CryoPort (NASDAQ:CYRX) Posts Quarterly Earnings Results, Misses Expectations By $0.03 EPS

CryoPort (NASDAQ:CYRX) issued its quarterly earnings data on Monday. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.03), Zacks reports. CryoPort had a negative return on equity of 7.84% and a net margin of 41.57%.The business had revenue of $47.80 million during the quarter, compared to the consensus estimate of $44.86 million.

Here are the key takeaways from CryoPort’s conference call:

• Cryoport reported $47.8 million in Q1 revenue, up 16% year‑over‑year, with commercial cell & gene therapy revenue +26% and clinical trial revenue +18%, and raised full‑year 2026 revenue guidance to $192–$196 million.
• Management expects to reach positive adjusted EBITDA in the second half of 2026 and delivered a $2.2 million year‑over‑year improvement in adjusted EBITDA from continuing operations in Q1.
• Cryoport is supporting a record 766 global clinical trials (net +55 YoY), including 91 Phase III trials, and now supports 21 commercial therapies with up to 8 additional potential approvals expected in 2026.
• Operational milestone — IntegriCell shipped its first cryopreserved clinical trial patient materials from Houston and Liège, signalling initial commercial activity for the integrated preservation service.
• Product strength — Life Sciences Products grew 15% driven by strong demand for MVE cryogenic systems and the new Fusion 800 Series, which management says expands addressable markets and supports a high‑single‑digit product growth outlook.

CryoPort Stock Up 1.5%

NASDAQ:CYRX traded up $0.18 on Wednesday, reaching $12.37. 91,229 shares of the company’s stock traded hands, compared to its average volume of 423,705. The stock has a 50-day simple moving average of $8.99 and a 200-day simple moving average of $9.34. CryoPort has a 12 month low of $5.31 and a 12 month high of $12.65. The firm has a market cap of $621.07 million, a PE ratio of 9.13 and a beta of 1.75.

Insider Transactions at CryoPort

In related news, CEO Jerrell Shelton sold 7,918 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $8.00, for a total transaction of $63,344.00. Following the completion of the sale, the chief executive officer owned 1,054,501 shares in the company, valued at approximately $8,436,008. This trade represents a 0.75% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark W. Sawicki sold 3,235 shares of CryoPort stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $8.00, for a total value of $25,880.00. Following the sale, the insider directly owned 103,697 shares in the company, valued at $829,576. This trade represents a 3.03% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 59,939 shares of company stock valued at $471,183 over the last 90 days. Company insiders own 10.10% of the company’s stock.

Institutional Trading of CryoPort

Several hedge funds have recently bought and sold shares of the stock. Millennium Management LLC boosted its holdings in shares of CryoPort by 23.8% during the 4th quarter. Millennium Management LLC now owns 3,244,802 shares of the company’s stock valued at $31,150,000 after purchasing an additional 623,896 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of CryoPort by 2.5% in the third quarter. Vanguard Group Inc. now owns 2,858,031 shares of the company’s stock worth $27,094,000 after purchasing an additional 69,550 shares during the last quarter. UBS Group AG lifted its position in shares of CryoPort by 112.7% in the third quarter. UBS Group AG now owns 1,331,521 shares of the company’s stock worth $12,623,000 after buying an additional 705,649 shares in the last quarter. Mak Capital One LLC boosted its stake in CryoPort by 46.6% during the fourth quarter. Mak Capital One LLC now owns 1,199,225 shares of the company’s stock valued at $11,513,000 after buying an additional 381,063 shares during the last quarter. Finally, State Street Corp boosted its stake in CryoPort by 0.8% during the fourth quarter. State Street Corp now owns 971,041 shares of the company’s stock valued at $9,322,000 after buying an additional 7,254 shares during the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Analyst Ratings Changes

CYRX has been the subject of several recent research reports. Wall Street Zen lowered CryoPort from a “hold” rating to a “sell” rating in a report on Sunday. Guggenheim lifted their price objective on CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research report on Tuesday. Weiss Ratings reiterated a “sell (d+)” rating on shares of CryoPort in a research note on Friday, March 27th. Needham & Company LLC raised their target price on shares of CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Tuesday. Finally, BTIG Research lifted their price target on shares of CryoPort from $15.00 to $17.00 and gave the company a “buy” rating in a report on Tuesday. Eight equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $14.44.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.